Goldman Sachs Maintains Buy on CareDx, Raises Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes has maintained a Buy rating on CareDx (NASDAQ:CDNA) and raised the price target from $26 to $35.
October 16, 2024 | 1:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs has reaffirmed its Buy rating on CareDx and increased the price target from $26 to $35, indicating a positive outlook.
The increase in price target from $26 to $35 by a reputable firm like Goldman Sachs suggests a strong positive outlook for CareDx. This is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100